查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2128131

藥物研發外包市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Drug Discovery Outsourcing Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 261 Pages | 商品交期: 2-3個工作天內

價格

藥物研發外包市場的成長要素

全球藥物研發外包市場預計到2025年將達到80.8億美元，並從2026年的87.5億美元成長到2034年的169.3億美元，預測期內複合年成長率（CAGR）為8.6%。北美將引領全球市場，預計到2025年將佔37.38%的市場佔有率，這主要得益於製藥公司的強大實力、先進合約研究組織（CRO）的發展以及對藥物研發投入的增加。

藥物研發外包使製藥和生物技術公司能夠將標靶識別、先導化合物篩選、先導化合物最佳化、藥物化學、生物服務和毒性測試等研究活動委託給專業的合約研究組織 (CRO)。外包能夠降低研發成本、縮短研發週期，並獲得先進的科學專業知識和數位技術。慢性疾病負擔日益加重、藥物研發項目日益複雜以及生物技術領域研發管線不斷擴展是推動市場成長的主要因素。此外，查爾斯河實驗室 (Charles River Laboratories)、藥明康德 (Wuxi Aptech)、歐陸科技 (Eurofins Scientific) 和 Evotech 等公司不斷透過收購、合作和人工智慧驅動的藥物研發平台來提升其服務能力。

市場趨勢

藥物研發外包市場最重要的趨勢之一是人工智慧 (AI)、機器學習和計算藥物研發平台的日益普及。合約研究組織 (CRO) 擴大利用 AI 進行標靶識別、虛擬篩檢、先導化合物最佳化、生物標記發現和候選化合物優先排序。這些技術提高了研究效率，縮短了研發週期，並降低了後期臨床試驗失敗的風險。隨著製藥公司尋求更快、更經濟高效的藥物研發解決方案，對 AI 驅動的外包服務的需求持續成長。

市場促進因素

癌症、心血管疾病、神經系統疾病和感染疾病等慢性疾病的日益普遍，正顯著推動對創新療法的需求成長。隨著製藥和生技公司不斷拓展研發管線，藥物研發外包已成為一種有效利用專業科學知識並降低營運成本的策略。對個人化醫療、生技藥品和精準醫療的投資增加，也為市場成長提供了支撐。

市場限制因素

儘管藥物研發領域具有巨大的成長潛力，但對資料安全、智慧財產權保護和保密性的擔憂仍然限制市場成長。藥物研發計畫涉及極具價值的生物數據、分子結構、篩檢結果和專有研究成果。安全漏洞和未授權存取可能會延誤研發專案或導致寶貴智慧財產權的損失，因此一些公司在將關鍵研究活動外包時持謹慎態度。

市場機遇

合約研究組織（CRO）在印度、中國和巴西等新興市場的快速擴張帶來了巨大的成長機會。醫療保健支出不斷成長、政府政策利好、實驗室基礎設施不斷完善以及製藥投資增加，都促使跨國公司將研發活動外包給這些成本效益高的地區。自動化、雲端運算和數位化實驗室技術的日益普及進一步提升了外包能力。

市場挑戰

該行業面臨的一大挑戰是，一些開發中國家高度專業化的合約研究機構（CRO）數量有限。許多新興市場仍然缺乏藥物化學、毒理學研究、計算生物學、高通量篩檢和轉化研究的先進基礎設施。這限制了高度複雜的藥物研發專案的外包，並減緩了某些地區的市場滲透。

細分分析

就服務類型而言，受藥物化學、化合物合成和先導藥物最適化服務需求成長的推動，化學服務領域將在2025年引領市場。生物服務領域預計在整個預測期內也將保持強勁成長。

按藥物發現階段分類，預計到2025年，先導藥物最適化領域將佔最大的市場佔有率，因為製藥公司正在增加最佳化任務的外包，以加速藥物發現和開發。預計在整個預測期內，先導化合物篩選將保持強勁成長。

按藥物類型分類，小分子藥物預計將成為市場成長的主要驅動力，到2025年將佔68.9%的市場佔有率，這主要得益於一系列新型小分子療法的批准。隨著對生物製藥的需求持續成長，生物製藥領域預計將經歷更快速的成長。

按治療領域分類，腫瘤學仍然是最大的細分市場，這主要歸因於全球癌症負擔的加重以及對癌症藥物研發投入的增加。神經系統疾病、心血管疾病和感染疾病的外包需求也持續顯著。

按最終用戶分類，預計到 2025 年，製藥和生物技術公司將佔最大佔有率，這主要得益於研發支出增加、藥物研發管線擴大以及對 CRO 提供的專業研究服務日益成長的依賴。

區域展望

預計到2025年，北美市場規模將維持在30.2億美元，繼續維持全球最大市場的地位。該地區憑藉其優勢，包括先進的研究基礎設施、高額的醫藥研發投入、廣泛的外包服務以及眾多大型合約研究機構（CRO）的存在，佔市場主導地位。光是美國市場預計到2026年就將達到28.7億美元，繼續維持在全球的領先地位。

在德國、英國和其他歐洲國家擴大藥品研發、促進外包活動以及創造有利的法規結構的支持下，預計到 2026 年，歐洲的藥品市場規模將達到 23.3 億美元。

預計到 2026 年，亞太地區的市場規模將達到 24.5 億美元，這主要得益於生技公司的快速擴張、CRO 基礎設施的發展、政府對生命科學研究的支持，以及中國、印度和日本製藥生產能力的提高。

在拉丁美洲和中東及非洲地區，隨著對醫療保健基礎設施、研究機構和製藥業合作的投資不斷增加，預計將穩步成長。

目錄

第1章：引言

第2章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第3章：主要考慮因素

  • 2025年主要國家和地區主要疾病的流行情況
  • 2025年主要國家醫療保健支出概覽
  • 研發支出概覽，主要公司
  • 產業重大發展：合併、收購與合作。

第4章：2021-2034年全球藥物研發外包市場分析、洞察與預測

  • 市場分析、洞察與預測：按服務類型分類
    • 化學服務
      • 合成化學服務
      • 分析化學服務
      • 其他
    • 生物服務
      • 體外分析服務
      • 毒理學服務
      • 其他
  • 市場分析、洞察與預測：按藥物發現階段分類
    • 目標識別與檢驗
    • 命中識別
    • 點擊閱讀
    • 先導藥物最適化
    • 其他
  • 市場分析、洞察與預測：按藥物類型分類
    • 低分子化合物
    • 生物製劑
  • 市場分析、洞察與預測：按治療領域分類
    • 腫瘤學
    • 神經系統疾病
    • 感染疾病
    • 心血管疾病
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 製藥和生物技術公司
    • 學術研究機構
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第5章：北美藥物研發外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第6章：歐洲藥物研發外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第7章：亞太地區藥物研發外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 東南亞
    • 其他亞太國家

第8章：拉丁美洲藥物研發外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第9章：中東和非洲藥物研發外包市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Charles River Laboratories
    • WuXi AppTec
    • Labcorp
    • Evotec
    • Eurofins Scientific
    • Reaction Biology
    • Pharmaron
    • Aragen Life Sciences Ltd.
    • Sai Life Sciences Limited
    • Crown Bioscience
Product Code: FBI117736

Growth Factors of Drug Discovery Outsourcing Market

The global drug discovery outsourcing market was valued at USD 8.08 billion in 2025 and is projected to grow from USD 8.75 billion in 2026 to USD 16.93 billion by 2034, registering a CAGR of 8.6% during the forecast period. North America dominated the global market with a 37.38% market share in 2025, supported by the strong presence of pharmaceutical companies, advanced contract research organizations (CROs), and increasing investment in drug development.

Drug discovery outsourcing enables pharmaceutical and biotechnology companies to delegate research activities such as target identification, hit identification, lead optimization, medicinal chemistry, biology services, and toxicology studies to specialized CROs. Outsourcing helps reduce development costs, accelerate research timelines, and provide access to advanced scientific expertise and digital technologies. The growing burden of chronic diseases, increasing complexity of drug development programs, and expanding biotech pipelines are major factors driving market growth. Furthermore, companies such as Charles River Laboratories, WuXi AppTec, Eurofins Scientific, and Evotec continue to strengthen their service capabilities through acquisitions, collaborations, and AI-enabled drug discovery platforms.

Market Trends

One of the most significant trends shaping the drug discovery outsourcing market is the growing adoption of artificial intelligence (AI), machine learning, and computational drug discovery platforms. CROs are increasingly utilizing AI for target identification, virtual screening, lead optimization, biomarker discovery, and candidate prioritization. These technologies improve research efficiency, reduce development timelines, and lower late-stage clinical failure risks. As pharmaceutical companies seek faster and more cost-effective drug discovery solutions, demand for AI-enabled outsourcing services continues to rise.

Market Drivers

The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological diseases, and infectious diseases is significantly increasing demand for innovative therapies. As pharmaceutical and biotechnology companies expand their research pipelines, outsourcing drug discovery activities has become an effective strategy for reducing operational costs while gaining access to specialized scientific expertise. Increasing investments in personalized medicine, biologics, and precision therapeutics are also supporting market expansion.

Market Restraints

Despite strong growth potential, concerns regarding data security, intellectual property protection, and confidentiality continue to restrain market growth. Drug discovery projects involve highly valuable biological data, molecular structures, screening results, and proprietary research. Any security breach or unauthorized access can delay development programs and expose valuable intellectual property, making some companies cautious about outsourcing critical research activities.

Market Opportunities

The rapid expansion of contract research organizations (CROs) across emerging markets such as India, China, and Brazil presents substantial growth opportunities. Growing healthcare expenditure, favorable government initiatives, expanding laboratory infrastructure, and increasing pharmaceutical investments are encouraging multinational companies to outsource research activities to these cost-effective regions. Rising adoption of automation, cloud computing, and digital laboratory technologies further enhances outsourcing capabilities.

Market Challenges

A major challenge for the industry is the limited availability of highly specialized CROs in several developing countries. Many emerging markets still lack advanced infrastructure for medicinal chemistry, toxicology studies, computational biology, high-throughput screening, and translational research. This limits the outsourcing of highly complex drug discovery projects and slows market penetration in certain regions.

Segmentation Analysis

Based on service type, the chemistry services segment dominated the market in 2025 due to increasing demand for medicinal chemistry, compound synthesis, and lead optimization services. The biology services segment is expected to witness strong growth throughout the forecast period.

By discovery phase, the lead optimization segment accounted for the largest market share in 2025 as pharmaceutical companies increasingly outsource optimization activities to accelerate drug development. Hit identification is expected to register healthy growth over the forecast period.

Based on drug type, small molecules dominated the market with a 68.9% share in 2025, driven by continuous approvals of novel small-molecule therapies. The biologics segment is anticipated to experience faster growth as demand for biologic drugs continues to increase.

By therapeutic area, oncology remained the leading segment due to the growing global cancer burden and increasing investments in oncology drug development. Neurological disorders, cardiovascular diseases, and infectious diseases also continue to generate substantial outsourcing demand.

Based on end user, pharmaceutical and biotechnology companies accounted for the largest share in 2025 owing to rising R&D expenditure, expanding drug pipelines, and increasing dependence on CROs for specialized research services.

Regional Outlook

North America remained the largest regional market with a value of USD 3.02 billion in 2025. The region benefits from advanced research infrastructure, high pharmaceutical R&D spending, widespread adoption of outsourcing services, and the presence of leading CROs. The U.S. market alone is estimated to reach USD 2.87 billion in 2026, maintaining its dominant global position.

Europe is expected to reach USD 2.33 billion in 2026, supported by increasing outsourcing activities, favorable regulatory frameworks, and expanding pharmaceutical research across Germany, the U.K., and other European countries.

Asia Pacific is projected to reach USD 2.45 billion in 2026, driven by the rapid expansion of biotechnology companies, increasing CRO infrastructure, government support for life sciences research, and growing pharmaceutical manufacturing capabilities in China, India, and Japan.

Latin America and the Middle East & Africa are anticipated to witness steady growth as investments in healthcare infrastructure, research institutes, and pharmaceutical collaborations continue to increase.

Competitive Landscape

The global drug discovery outsourcing market is highly competitive, with major players focusing on acquisitions, strategic collaborations, AI integration, and expansion of laboratory capabilities to strengthen their market positions. Leading companies include Charles River Laboratories, WuXi AppTec, Labcorp, Evotec, Eurofins Scientific, Reaction Biology, Pharmaron, Aragen Life Sciences, Sai Life Sciences, and Crown Bioscience. Recent strategic initiatives, including acquisitions, AI-driven discovery platforms, and expanded biologics capabilities, continue to improve service offerings and global competitiveness.

Key Industry Developments

Recent developments highlight the industry's rapid evolution. In July 2026, Eurofins Scientific acquired DiscoveryBioMed to strengthen human bioassay capabilities. In April 2026, WuXi AppTec showcased multiple oncology drug discovery innovations at AACR 2026. Sai Life Sciences partnered with Chemical.AI in March 2026 to integrate AI-powered retrosynthesis into discovery chemistry workflows. Charles River Laboratories acquired PathoQuest in January 2026 to expand biologics testing services. In October 2025, Pharmaron strengthened its protein science capabilities through the acquisition of Biortus Biosciences, while several collaborations across AI-based molecular modeling and drug discovery technologies continue to accelerate innovation.

Conclusion

The global drug discovery outsourcing market is positioned for robust growth as pharmaceutical and biotechnology companies increasingly rely on specialized CROs to improve research efficiency, reduce development costs, and accelerate drug discovery timelines. Rising chronic disease prevalence, expanding biotech pipelines, AI-enabled discovery platforms, and increasing investments in personalized medicine will continue driving market expansion. With the market expected to grow from USD 8.75 billion in 2026 to USD 16.93 billion by 2034, outsourcing is expected to remain a critical component of modern pharmaceutical research and innovation.

Segmentation By Service Type, Discovery Phase, Drug Type, Therapeutic Area, End User, and Region

By Service Type * Chemistry Services

    • Synthetic Chemistry Services
    • Analytical Chemistry Services
    • Others
  • Biology Services
    • In-vitro Profiling Services
    • Toxicology Services
    • Others

By Discovery Phase * Target Identification & Validation

  • Hit Identification
  • Hit-to-Lead
  • Lead Optimization
  • Others

By Drug Type * Small Molecules

  • Biologics

By Therapeutic Area * Oncology

  • Neurological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

By End User * Pharmaceutical & Biotechnological Companies

  • Academic & Research Institutes
  • Others

By Region * North America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country)

    • U.S. (By Drug Type)
    • Canada (By Drug Type)
  • Europe (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
    • U.K. (By Drug Type)
    • Germany (By Drug Type)
    • France (By Drug Type)
    • Italy (By Drug Type)
    • Spain (By Drug Type)
    • Scandinavia (By Drug Type)
    • Rest of Europe (By Drug Type)
  • Asia Pacific (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
    • China (By Drug Type)
    • Japan (By Drug Type)
    • India (By Drug Type)
    • Australia (By Drug Type)
    • Southeast Asia (By Drug Type)
    • Rest of Asia Pacific (By Drug Type)
  • Latin America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
    • Brazil (By Drug Type)
    • Mexico (By Drug Type)
    • Rest of Latin America (By Drug Type)
  • Middle East & Africa (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
    • GCC (By Drug Type)
    • South Africa (By Drug Type)
    • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Executive Summary

2. Market Dynamics

  • 2.1. Market Drivers
  • 2.2. Market Restraints
  • 2.3. Market Opportunities
  • 2.4. Market Challenges
  • 2.5. Market Trends

3. Key Insights

  • 3.1. Prevalence of Key Disorders, Key Countries/Region, 2025
  • 3.2. Overview of Healthcare Expenditure, Key Countries, 2025
  • 3.3. Overview of R&D Expenditures, Key Players
  • 3.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

4. Global Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 4.1. Market Analysis, Insights and Forecast - By Service Type
    • 4.1.1. Chemistry Services
      • 4.1.1.1. Synthetic Chemistry Services
      • 4.1.1.2. Analytical Chemistry Services
      • 4.1.1.3. Others
    • 4.1.2. Biology Services
      • 4.1.2.1. In-vitro Profiling Services
      • 4.1.2.2. Toxicology Services
      • 4.1.2.3. Others
  • 4.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 4.2.1. Target Identification & Validation
    • 4.2.2. Hit Identification
    • 4.2.3. Hit-to-Lead
    • 4.2.4. Lead Optimization
    • 4.2.5. Others
  • 4.3. Market Analysis, Insights and Forecast - By Drug Type
    • 4.3.1. Small Molecules
    • 4.3.2. Biologics
  • 4.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 4.4.1. Oncology
    • 4.4.2. Neurological Diseases
    • 4.4.3. Infectious Diseases
    • 4.4.4. Cardiovascular Diseases
    • 4.4.5. Others
  • 4.5. Market Analysis, Insights and Forecast - By End User
    • 4.5.1. Pharmaceutical & Biotechnological Companies
    • 4.5.2. Academic & Research Institutes
    • 4.5.3. Others
  • 4.6. Market Analysis, Insights and Forecast - By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa

5. North America Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Service Type
    • 5.1.1. Chemistry Services
      • 5.1.1.1. Synthetic Chemistry Services
      • 5.1.1.2. Analytical Chemistry Services
      • 5.1.1.3. Others
    • 5.1.2. Biology Services
      • 5.1.2.1. In-vitro Profiling Services
      • 5.1.2.2. Toxicology Services
      • 5.1.2.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 5.2.1. Target Identification & Validation
    • 5.2.2. Hit Identification
    • 5.2.3. Hit-to-Lead
    • 5.2.4. Lead Optimization
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Drug Type
    • 5.3.1. Small Molecules
    • 5.3.2. Biologics
  • 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 5.4.1. Oncology
    • 5.4.2. Neurological Diseases
    • 5.4.3. Infectious Diseases
    • 5.4.4. Cardiovascular Diseases
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Pharmaceutical & Biotechnological Companies
    • 5.5.2. Academic & Research Institutes
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Country
    • 5.6.1. U.S.
      • 5.6.1.1. By Drug Type
    • 5.6.2. Canada
      • 5.6.2.1. By Drug Type

6. Europe Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Service Type
    • 6.1.1. Chemistry Services
      • 6.1.1.1. Synthetic Chemistry Services
      • 6.1.1.2. Analytical Chemistry Services
      • 6.1.1.3. Others
    • 6.1.2. Biology Services
      • 6.1.2.1. In-vitro Profiling Services
      • 6.1.2.2. Toxicology Services
      • 6.1.2.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 6.2.1. Target Identification & Validation
    • 6.2.2. Hit Identification
    • 6.2.3. Hit-to-Lead
    • 6.2.4. Lead Optimization
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Drug Type
    • 6.3.1. Small Molecules
    • 6.3.2. Biologics
  • 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 6.4.1. Oncology
    • 6.4.2. Neurological Diseases
    • 6.4.3. Infectious Diseases
    • 6.4.4. Cardiovascular Diseases
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Pharmaceutical & Biotechnological Companies
    • 6.5.2. Academic & Research Institutes
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.6.1. U.K.
      • 6.6.1.1. By Drug Type
    • 6.6.2. Germany
      • 6.6.2.1. By Drug Type
    • 6.6.3. France
      • 6.6.3.1. By Drug Type
    • 6.6.4. Spain
      • 6.6.4.1. By Drug Type
    • 6.6.5. Italy
      • 6.6.5.1. By Drug Type
    • 6.6.6. Scandinavia
      • 6.6.6.1. By Drug Type
    • 6.6.7. Rest of Europe
      • 6.6.7.1. By Drug Type

7. Asia Pacific Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Service Type
    • 7.1.1. Chemistry Services
      • 7.1.1.1. Synthetic Chemistry Services
      • 7.1.1.2. Analytical Chemistry Services
      • 7.1.1.3. Others
    • 7.1.2. Biology Services
      • 7.1.2.1. In-vitro Profiling Services
      • 7.1.2.2. Toxicology Services
      • 7.1.2.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 7.2.1. Target Identification & Validation
    • 7.2.2. Hit Identification
    • 7.2.3. Hit-to-Lead
    • 7.2.4. Lead Optimization
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Drug Type
    • 7.3.1. Small Molecules
    • 7.3.2. Biologics
  • 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 7.4.1. Oncology
    • 7.4.2. Neurological Diseases
    • 7.4.3. Infectious Diseases
    • 7.4.4. Cardiovascular Diseases
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Pharmaceutical & Biotechnological Companies
    • 7.5.2. Academic & Research Institutes
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. Japan
      • 7.6.1.1. By Drug Type
    • 7.6.2. Australia
      • 7.6.2.1. By Drug Type
    • 7.6.3. China
      • 7.6.3.1. By Drug Type
    • 7.6.4. India
      • 7.6.4.1. By Drug Type
    • 7.6.5. Southeast Asia
      • 7.6.5.1. By Drug Type
    • 7.6.6. Rest of Asia Pacific
      • 7.6.6.1. By Drug Type

8. Latin America Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Service Type
    • 8.1.1. Chemistry Services
      • 8.1.1.1. Synthetic Chemistry Services
      • 8.1.1.2. Analytical Chemistry Services
      • 8.1.1.3. Others
    • 8.1.2. Biology Services
      • 8.1.2.1. In-vitro Profiling Services
      • 8.1.2.2. Toxicology Services
      • 8.1.2.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 8.2.1. Target Identification & Validation
    • 8.2.2. Hit Identification
    • 8.2.3. Hit-to-Lead
    • 8.2.4. Lead Optimization
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Drug Type
    • 8.3.1. Small Molecules
    • 8.3.2. Biologics
  • 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 8.4.1. Oncology
    • 8.4.2. Neurological Diseases
    • 8.4.3. Infectious Diseases
    • 8.4.4. Cardiovascular Diseases
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Pharmaceutical & Biotechnological Companies
    • 8.5.2. Academic & Research Institutes
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Brazil
      • 8.6.1.1. By Drug Type
    • 8.6.2. Mexico
      • 8.6.2.1. By Drug Type
    • 8.6.3. Rest of Latin America
      • 8.6.3.1. By Drug Type

9. Middle East & Africa Drug Discovery Outsourcing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Service Type
    • 9.1.1. Chemistry Services
      • 9.1.1.1. Synthetic Chemistry Services
      • 9.1.1.2. Analytical Chemistry Services
      • 9.1.1.3. Others
    • 9.1.2. Biology Services
      • 9.1.2.1. In-vitro Profiling Services
      • 9.1.2.2. Toxicology Services
      • 9.1.2.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Discovery Phase
    • 9.2.1. Target Identification & Validation
    • 9.2.2. Hit Identification
    • 9.2.3. Hit-to-Lead
    • 9.2.4. Lead Optimization
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Drug Type
    • 9.3.1. Small Molecules
    • 9.3.2. Biologics
  • 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 9.4.1. Oncology
    • 9.4.2. Neurological Diseases
    • 9.4.3. Infectious Diseases
    • 9.4.4. Cardiovascular Diseases
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Pharmaceutical & Biotechnological Companies
    • 9.5.2. Academic & Research Institutes
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. GCC
      • 9.6.1.1. By Drug Type
    • 9.6.2. South Africa
      • 9.6.2.1. By Drug Type
    • 9.6.3. Rest of Middle East & Africa
      • 9.6.3.1. By Drug Type

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Charles River Laboratories
    • 10.2.2. WuXi AppTec
    • 10.2.3. Labcorp
    • 10.2.4. Evotec
    • 10.2.5. Eurofins Scientific
    • 10.2.6. Reaction Biology
    • 10.2.7. Pharmaron
    • 10.2.8. Aragen Life Sciences Ltd.
    • 10.2.9. Sai Life Sciences Limited
    • 10.2.10. Crown Bioscience

List of Tables

  • Table 1: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 2: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 3: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 4: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 5: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 6: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 7: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 8: Global Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 9: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 10: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 11: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 12: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 13: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 15: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 16: North America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 17: U.S. Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 18: Canada Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 19: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 20: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 21: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 22: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 23: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 24: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 25: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 26: Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 27: Germany Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 28: U.K. Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 29: France Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 30: Italy Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 31: Spain Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 32: Scandinavia Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 33: Rest of Europe Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 34: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 35: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 36: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 37: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 38: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 39: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 40: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 41: Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 42: China Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 43: Japan Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 44: India Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 45: Australia Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 46: Southeast Asia Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 47: Rest of Asia Pacific Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 48: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 49: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 50: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 51: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 52: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 53: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 54: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 55: Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 56: Brazil Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 57: Mexico Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 58: Rest of Latin America Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 59: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Service Type, 2021-2034
  • Table 60: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Chemistry Services, 2021-2034
  • Table 61: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Biology Services, 2021-2034
  • Table 62: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Discovery Phase, 2021-2034
  • Table 63: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 64: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Therapeutic Area, 2021-2034
  • Table 65: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 66: Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 67: GCC Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 68: South Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 69: Rest of Middle East & Africa Drug Discovery Outsourcing Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034

List of Figures

  • Figure 1: Global Drug Discovery Outsourcing Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025 & 2034
  • Figure 3: Global Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025 & 2034
  • Figure 4: Global Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 5: Global Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025 & 2034
  • Figure 6: Global Drug Discovery Outsourcing Market Value Share (%), by End User, 2025 & 2034
  • Figure 7: Global Drug Discovery Outsourcing Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Drug Discovery Outsourcing Market Value (USD billion), by Service Type, 2025 & 2034
  • Figure 9: North America Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025
  • Figure 10: North America Drug Discovery Outsourcing Market Value (USD billion), by Discovery Phase, 2025 & 2034
  • Figure 11: North America Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025
  • Figure 12: North America Drug Discovery Outsourcing Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 13: North America Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025
  • Figure 14: North America Drug Discovery Outsourcing Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 15: North America Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025
  • Figure 16: North America Drug Discovery Outsourcing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 17: North America Drug Discovery Outsourcing Market Value Share (%), by End User, 2025
  • Figure 18: North America Drug Discovery Outsourcing Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Drug Discovery Outsourcing Market Value Share (%), By Country, 2025
  • Figure 20: Europe Drug Discovery Outsourcing Market Value (USD billion), by Service Type, 2025 & 2034
  • Figure 21: Europe Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025
  • Figure 22: Europe Drug Discovery Outsourcing Market Value (USD billion), by Discovery Phase, 2025 & 2034
  • Figure 23: Europe Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025
  • Figure 24: Europe Drug Discovery Outsourcing Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 25: Europe Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025
  • Figure 26: Europe Drug Discovery Outsourcing Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 27: Europe Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025
  • Figure 28: Europe Drug Discovery Outsourcing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 29: Europe Drug Discovery Outsourcing Market Value Share (%), by End User, 2025
  • Figure 30: Europe Drug Discovery Outsourcing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Drug Discovery Outsourcing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), by Service Type, 2025 & 2034
  • Figure 33: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025
  • Figure 34: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), by Discovery Phase, 2025 & 2034
  • Figure 35: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025
  • Figure 36: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 37: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025
  • Figure 38: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 39: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025
  • Figure 40: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 41: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), by End User, 2025
  • Figure 42: Asia Pacific Drug Discovery Outsourcing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Drug Discovery Outsourcing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Drug Discovery Outsourcing Market Value (USD billion), by Service Type, 2025 & 2034
  • Figure 45: Latin America Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025
  • Figure 46: Latin America Drug Discovery Outsourcing Market Value (USD billion), by Discovery Phase, 2025 & 2034
  • Figure 47: Latin America Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025
  • Figure 48: Latin America Drug Discovery Outsourcing Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 49: Latin America Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025
  • Figure 50: Latin America Drug Discovery Outsourcing Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 51: Latin America Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025
  • Figure 52: Latin America Drug Discovery Outsourcing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 53: Latin America Drug Discovery Outsourcing Market Value Share (%), by End User, 2025
  • Figure 54: Latin America Drug Discovery Outsourcing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Drug Discovery Outsourcing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), by Service Type, 2025 & 2034
  • Figure 57: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), by Service Type, 2025
  • Figure 58: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), by Discovery Phase, 2025 & 2034
  • Figure 59: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), by Discovery Phase, 2025
  • Figure 60: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 61: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), by Drug Type, 2025
  • Figure 62: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), by Therapeutic Area, 2025 & 2034
  • Figure 63: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), by Therapeutic Area, 2025
  • Figure 64: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 65: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), by End User, 2025
  • Figure 66: Middle East & Africa Drug Discovery Outsourcing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Drug Discovery Outsourcing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Drug Discovery Outsourcing Market Share (%), By Company, 2025